Dr. Jethro Ekuta Joins BP Logix Life Sciences Strategic Advisory Board
SAN DIEGO--(BUSINESS WIRE)--BP Logix, a leading provider of AI-enabled medical affairs automation technology, is proud to announce the appointment of Dr. Jethro Ekuta to its Life Sciences Strategic Advisory Board.
'I believe BP Logix is uniquely positioned to help life sciences organizations streamline compliance, reduce risk and move faster without compromising integrity."
Share
Dr. Ekuta is the Chair of the Board of Directors for the Regulatory Affairs Professionals Society (RAPS) and currently serves as Chief Regulatory & Safety Officer at Ascendis Pharma.
With over 30 years of experience in regulatory affairs and pharmacovigilance, Dr. Ekuta brings a deep understanding of global compliance, regulatory strategy and innovation in drug development. He has held senior leadership roles at organizations including Ascendis Pharma, Alexion (AstraZeneca Rare Disease), Horizon Therapeutics (Amgen), Johnson & Johnson, Genzyme (Sanofi), Bristol-Myers Squibb, Pfizer and the U.S. Food and Drug Administration (FDA).
'We are honored to welcome Dr. Ekuta to our Life Sciences Strategic Advisory Board,' said Girish Pashilkar, CEO of BP Logix. 'His regulatory insight and leadership will be instrumental as we continue to expand our footprint in the life sciences sector and support teams navigating increasingly complex review and approval processes.'
'I've spent my career working to improve regulatory systems and processes within the pharmaceutical and biotech industries,' said Dr. Ekuta. 'I believe BP Logix is uniquely positioned to help life sciences organizations streamline compliance, reduce risk and move faster without compromising integrity. I'm excited to contribute to the company's mission and support its growth in this critical space.'
In his advisory role, Dr. Ekuta will provide strategic input across marketing, product, and customer engagement initiatives. His appointment is part of a broader effort by BP Logix to deepen its alignment with industry leaders and further tailor its solutions to the evolving needs of life sciences organizations.
About BP Logix
BP Logix helps medical affairs and regulatory teams at life sciences organizations streamline complex review and approval workflows. Its flagship solution, PubPro, simplifies the publication process, while the broader Approvia platform supports use cases such as MLR reviews, clearance systems, medical information requests and IIS evaluations. With a focus on configurability, compliance and speed, BP Logix empowers teams to reduce risk, improve collaboration and bring high-quality treatments to market faster.
To learn more about BP Logix and its work in life sciences, visit www.bplogix.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 days ago
- Yahoo
Ascendis Pharma (ASND) Rated as a Hold at Cannacord Genuity on Growth Hormone Prospects
Ascendis Pharma A/S (NASDAQ:ASND) is among the 12 best healthcare stocks to buy now. On June 10, Canaccord Genuity reiterated a Hold rating on the stock and an $84 price target. The stance follows the release of new clinical trial data. A close-up of a researcher in a biopharmaceutical lab, carefully studying a sample. The pharmaceutical company delivered solid 26-week efficacy results from its TransCon HGH+TransCon CNP COACH trial. Nevertheless, the research firm raised concerns over potential long-term side effects of the human Growth Hormone under investigation. The remarks reflect a cautious optimism while considering the broader competitive landscape and long-term implications. Consequently, while the candidate treatment offers an additional growth acceleration option, it might not be a permanent replacement for CNP immunotherapy in achondroplasia patients. On its part, Ascendis Pharma insists that the combination treatment presents an alternative therapeutic choice that patients and caregivers can rely on. The US Food and Drug Administration has accepted the company's New Drug Application for TransCon. The approval follows the treatment's significant benefits in annualized growth velocity and health improvements in Children. Ascendis Pharma A/S (NASDAQ:ASND) is a biopharma company focused on developing innovative treatments for unmet medical needs, especially in the fields of endocrinology and oncology. The company utilizes its proprietary TransCon technology platform to design therapies that aim to deliver improved outcomes and set new standards in care. While we acknowledge the potential of ASND as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Stocks Analysts Are Upgrading Today and 13 Best AI Stocks to Buy Under $10. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Yahoo
Dr. Jethro Ekuta Joins BP Logix Life Sciences Strategic Advisory Board
Global regulatory leader brings decades of experience to guide the next generation of medical affairs automation. SAN DIEGO, June 16, 2025--(BUSINESS WIRE)--BP Logix, a leading provider of AI-enabled medical affairs automation technology, is proud to announce the appointment of Dr. Jethro Ekuta to its Life Sciences Strategic Advisory Board. Dr. Ekuta is the Chair of the Board of Directors for the Regulatory Affairs Professionals Society (RAPS) and currently serves as Chief Regulatory & Safety Officer at Ascendis Pharma. With over 30 years of experience in regulatory affairs and pharmacovigilance, Dr. Ekuta brings a deep understanding of global compliance, regulatory strategy and innovation in drug development. He has held senior leadership roles at organizations including Ascendis Pharma, Alexion (AstraZeneca Rare Disease), Horizon Therapeutics (Amgen), Johnson & Johnson, Genzyme (Sanofi), Bristol-Myers Squibb, Pfizer and the U.S. Food and Drug Administration (FDA). "We are honored to welcome Dr. Ekuta to our Life Sciences Strategic Advisory Board," said Girish Pashilkar, CEO of BP Logix. "His regulatory insight and leadership will be instrumental as we continue to expand our footprint in the life sciences sector and support teams navigating increasingly complex review and approval processes." "I've spent my career working to improve regulatory systems and processes within the pharmaceutical and biotech industries," said Dr. Ekuta. "I believe BP Logix is uniquely positioned to help life sciences organizations streamline compliance, reduce risk and move faster without compromising integrity. I'm excited to contribute to the company's mission and support its growth in this critical space." In his advisory role, Dr. Ekuta will provide strategic input across marketing, product, and customer engagement initiatives. His appointment is part of a broader effort by BP Logix to deepen its alignment with industry leaders and further tailor its solutions to the evolving needs of life sciences organizations. About BP Logix BP Logix helps medical affairs and regulatory teams at life sciences organizations streamline complex review and approval workflows. Its flagship solution, PubPro, simplifies the publication process, while the broader Approvia platform supports use cases such as MLR reviews, clearance systems, medical information requests and IIS evaluations. With a focus on configurability, compliance and speed, BP Logix empowers teams to reduce risk, improve collaboration and bring high-quality treatments to market faster. To learn more about BP Logix and its work in life sciences, visit View source version on Contacts Media contact: Catie Leary,
Associated Press
5 days ago
- Associated Press
Dr. Jethro Ekuta Joins BP Logix Life Sciences Strategic Advisory Board
SAN DIEGO--(BUSINESS WIRE)--Jun 16, 2025-- BP Logix, a leading provider of AI-enabled medical affairs automation technology, is proud to announce the appointment of Dr. Jethro Ekuta to its Life Sciences Strategic Advisory Board. This press release features multimedia. View the full release here: Dr. Jethro Ekuta, member of the BP Logix Life Sciences Strategic Advisory Board. Dr. Ekuta is the Chair of the Board of Directors for the Regulatory Affairs Professionals Society (RAPS) and currently serves as Chief Regulatory & Safety Officer at Ascendis Pharma. With over 30 years of experience in regulatory affairs and pharmacovigilance, Dr. Ekuta brings a deep understanding of global compliance, regulatory strategy and innovation in drug development. He has held senior leadership roles at organizations including Ascendis Pharma, Alexion (AstraZeneca Rare Disease), Horizon Therapeutics (Amgen), Johnson & Johnson, Genzyme (Sanofi), Bristol-Myers Squibb, Pfizer and the U.S. Food and Drug Administration (FDA). 'We are honored to welcome Dr. Ekuta to our Life Sciences Strategic Advisory Board,' said Girish Pashilkar, CEO of BP Logix. 'His regulatory insight and leadership will be instrumental as we continue to expand our footprint in the life sciences sector and support teams navigating increasingly complex review and approval processes.' 'I've spent my career working to improve regulatory systems and processes within the pharmaceutical and biotech industries,' said Dr. Ekuta. 'I believe BP Logix is uniquely positioned to help life sciences organizations streamline compliance, reduce risk and move faster without compromising integrity. I'm excited to contribute to the company's mission and support its growth in this critical space.' In his advisory role, Dr. Ekuta will provide strategic input across marketing, product, and customer engagement initiatives. His appointment is part of a broader effort by BP Logix to deepen its alignment with industry leaders and further tailor its solutions to the evolving needs of life sciences organizations. About BP Logix BP Logix helps medical affairs and regulatory teams at life sciences organizations streamline complex review and approval workflows. Its flagship solution, PubPro, simplifies the publication process, while the broader Approvia platform supports use cases such as MLR reviews, clearance systems, medical information requests and IIS evaluations. With a focus on configurability, compliance and speed, BP Logix empowers teams to reduce risk, improve collaboration and bring high-quality treatments to market faster. To learn more about BP Logix and its work in life sciences, visit View source version on Media contact: Catie Leary, [email protected] KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: TECHNOLOGY HEALTH TECHNOLOGY SOFTWARE NETWORKS INTERNET MANAGED CARE HEALTH DATA MANAGEMENT ARTIFICIAL INTELLIGENCE SOURCE: BP Logix Copyright Business Wire 2025. PUB: 06/16/2025 07:00 AM/DISC: 06/16/2025 06:59 AM
